Change ahead for cancer drug funding.
出版信息
Lancet Haematol. 2015 Feb;2(2):e47. doi: 10.1016/S2352-3026(15)00007-1. Epub 2015 Feb 5.
Abstract
摘要
相似文献
1
Change ahead for cancer drug funding.
Lancet Haematol. 2015 Feb;2(2):e47. doi: 10.1016/S2352-3026(15)00007-1. Epub 2015 Feb 5.
2
A question of health. The lottery of cancer care.
Health Serv J. 1997 Dec 18;107(5584):suppl 1-4 following 24.
3
Pharmaceutical funding decisions must balance therapeutic innovation, opportunity costs and patient equity.
N Z Med J. 2016 Aug 19;129(1440):22-4.
4
Key changes to cancer care in the UK.
Br J Nurs. 2015;24(4):S3. doi: 10.12968/bjon.2015.24.Sup4.S3.
5
Cancer drugs fund receives boost but will no longer fund "overpriced" drugs.
BMJ. 2014 Sep 1;349:g5382. doi: 10.1136/bmj.g5382.
6
Cancer charity demands extension of drug fund despite criticisms it is unfair.
BMJ. 2014 Oct 28;349:g6507. doi: 10.1136/bmj.g6507.
7
UK Cancer Drugs Fund to reassess 42 agents.
Lancet Oncol. 2015 Jan;16(1):e8. doi: 10.1016/S1470-2045(14)71137-4. Epub 2014 Nov 21.
8
Adjuvant trastuzumab for breast cancer: the other side of the coin.
BMJ. 2005 Nov 19;331(7526):1202-3. doi: 10.1136/bmj.331.7526.1202-c.
9
Cancer drugs dropped from 'unsustainable' fund list.
Nurs Stand. 2015 Sep 23;30(4):10. doi: 10.7748/ns.30.4.10.s11.
10
Limits to Personalized Cancer Medicine.
N Engl J Med. 2016 Sep 29;375(13):1289-94. doi: 10.1056/NEJMsb1607705.
引用本文的文献
1
Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
Patient. 2016 Jun;9(3):201-22. doi: 10.1007/s40271-015-0139-7.
Zotero 插件